C112P: Vandortuzumab Biosimilar, Anti-STEAP1 Monoclonal Antibody

Catalog No.: C112P | **Product Name:** Vandortuzumab Biosimilar, Anti-STEAP1 Monoclonal Antibody

The research grade Vandortuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C112P
Product Name	Vandortuzumab Biosimilar, Anti-STEAP1 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	PRSS24, STEAP, STEAP1
Summary	Recombinant Humanized IgG1 kappa Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-STEAP1 monoclonal antibody vandortuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade vandortuzumab biosimilar specifically binds to the STEAP1 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by vandortuzumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Vandortuzumab Biosimilar, Anti-STEAP1 Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Vandortuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is vandortuzumab biosimilar research grade? Vandortuzumab is a humanized IgG1 monoclonal antibody that targets six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a cell-surface antigen highly expressed on prostate cancer cells and other tumors. STEAP1 is involved in intercellular communication and is overexpressed in a majority of prostate cancers. Vandortuzumab has been investigated as an antibody-drug conjugate (ADC) payload carrier and for imaging applications in prostate cancer. Vandortuzumab biosimilar uses the same protein sequences as the therapeutic antibody vandortuzumab.